Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

Heparin has traditionally been injected and used to treat blood clots, but the new study tested...

Government funding will enable researchers to test a suite of next-generation therapies they have...

Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...

Content from other channels on our network

Climate-positive landscapes win at design awards

Data centres — a missed opportunity for sustainability

151 battery electric buses announced for NSW

AI may help Australia prepare for hotter, drier summers

Melbourne Water wins at 2025 Victorian Water Awards

Securing industrial networks: three architecture strategies

Largest shipbuilder in the US places AML3D's largest order so far

ARENA backs no‍-‍inverter battery storage technology

Magnetic flow meters: Verification and calibration within the process

ABB to divest Robotics division

On the rise: consumer trust in the red meat industry

Fonterra invests NZ$75m for new butter line at Clandeboye

Wineries get smart with sensors to prevent overspill

Enartis to acquire Parsec in a wine industry deal

Six on the shelf: Summer treats by the block load